You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
The Risk of Subsequent Malignancies in Women With Uterine Papillary Serous or Clear Cell Endometrial Cancers
  1. Hilary D. Hinshaw, MD*,
  2. Ashlee Smith, DO*,
  3. Bunja Rungruang, MD*,
  4. Joseph L. Kelley, MD*,
  5. Sushil Beriwal, MD†,
  6. Thomas C. Krivak, MD*,
  7. Paniti Sukumvanich, MD* and
  8. Alexander B. Olawaiye, MD*
  1. *Divisions of Gynecologic Oncology and
  2. †Divisions of Radiation Oncology, Magee-Women’s Hospital of UPMC, Pittsburgh, PA.
  1. Address correspondence and reprint requests to Alexander B. Olawaiye, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Magee-Women’s Hospital of UPMC, 300 Halket St, Pittsburgh, PA 15213. E-mail: olawaiyea@mail.magee.edu.

Abstract

Objective Type II endometrial cancers include uterine papillary serous carcinoma (UPSC) and clear cell endometrial cancer (CC). Given their relative rarity, aggressive nature, and poor prognosis, little is known about the risk of subsequent malignancies at other sites. Our objective was to determine if women with UPSC or CC are at increased risk of subsequent malignancies.

Type II endometrial cancers include uterine papillary serous carcinoma (UPSC) and clear cell endometrial cancer (CC). Given their relative rarity, aggressive nature, and poor prognosis, little is known about the risk of subsequent malignancies at other sites. Our objective was to determine if women with UPSC or CC are at increased risk of subsequent malignancies.

Methods Women diagnosed with UPSC or CC were identified from the SEER (Surveillance Epidemiology and End Results) Program from 1973 to 2005. Cases with a second gynecologic malignancy were excluded. Using SEER*Stat software, standardized incidence ratios (SIRs) of subsequent malignancies were calculated.

Results A total of 8045 and 1740 patients were diagnosed with UPSC and CC, respectively. Four hundred sixty-one (5.7%) of the UPSC cases were diagnosed with at least 1 additional nongynecologic malignancy. Significant associations were found with the following malignancies: the renal pelvis, soft-tissue sarcomas, acute myeloid leukemia, the bladder, and colon. Seventy-eight CC cases (4.5%) were diagnosed with at least 1 additional malignancy. In comparison with the baseline population risk, there was no statistically significant increased risk of any subsequent malignancy with a primary diagnosis of CC.

Conclusions This is the first large population-based analysis of second primary malignancies after type II endometrial cancers. Uterine papillary serous carcinoma is associated with increased risks of certain subsequent malignancies, and providers should be aware of these when following up patients with this diagnosis, especially those with stage I disease. In contrast, no such associations were found with CC in this cohort.

  • Clear cell endometrial cancer
  • Subsequent malignancies
  • Uterine papillary serous carcinoma
  • Type II endometrial cancer

http://dx.doi.org/10.1097/IGC.0b013e3182959053

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Dr Rungruang is now with the Division of Gynecologic Oncology, Medical College of Georgia, Augusta, GA.

    • No funding was received for this work.

    • The authors declare no conflicts of interest.